Subsidiary Hichi Pharmaceutical's Iodixanol API Obtains Korean Registration Certificate

Recently, Zhejiang Hichi Pharmaceutical Corporation Limited, a subsidiary of Beijing Beilu Pharmaceutical Co., Ltd., received the product registration certificate for Iodixanol API issued by the Korean Food and Drug Safety Administration (KFDA).

After successfully obtaining domestic market approval in September 2024, Hichi Pharmaceutical's Iodixanol API has now also received the Korean registration certificate. This means the product has successfully passed the review process by the relevant Korean authorities and officially obtained market access, allowing it to be sold in the Korean market. This achievement enhances the company's potential for expanding into international markets, provides solid support for steady growth in Hichi Pharmaceutical's API sales, and helps strengthen the company's competitiveness in relevant markets, further consolidating and expanding its market share.